These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

440 related articles for article (PubMed ID: 25305563)

  • 1. Simultaneous active intracellular delivery of doxorubicin and C6-ceramide shifts the additive/antagonistic drug interaction of non-encapsulated combination.
    Fonseca NA; Gomes-da-Silva LC; Moura V; Simões S; Moreira JN
    J Control Release; 2014 Dec; 196():122-31. PubMed ID: 25305563
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhanced Cytotoxicity of Folic Acid-Targeted Liposomes Co-Loaded with C6 Ceramide and Doxorubicin: In Vitro Evaluation on HeLa, A2780-ADR, and H69-AR Cells.
    Sriraman SK; Pan J; Sarisozen C; Luther E; Torchilin V
    Mol Pharm; 2016 Feb; 13(2):428-37. PubMed ID: 26702994
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nucleolin overexpression in breast cancer cell sub-populations with different stem-like phenotype enables targeted intracellular delivery of synergistic drug combination.
    Fonseca NA; Rodrigues AS; Rodrigues-Santos P; Alves V; Gregório AC; Valério-Fernandes Â; Gomes-da-Silva LC; Rosa MS; Moura V; Ramalho-Santos J; Simões S; Moreira JN
    Biomaterials; 2015 Nov; 69():76-88. PubMed ID: 26283155
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Engineered peptides for the development of actively tumor targeted liposomal carriers of doxorubicin.
    Shahin M; Soudy R; El-Sikhry H; Seubert JM; Kaur K; Lavasanifar A
    Cancer Lett; 2013 Jul; 334(2):284-92. PubMed ID: 23073474
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Co-delivery of doxorubicin and PEGylated C16-ceramide by nanoliposomes for enhanced therapy against multidrug resistance.
    Su X; Song H; Niu F; Yang K; Kou G; Wang X; Chen H; Li W; Guo S; Li J; Li B; Feng SS; Jiang J; Yin C; Gao J
    Nanomedicine (Lond); 2015; 10(13):2033-50. PubMed ID: 26084553
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of transferrin receptor-targeted liposomal doxorubicin in P-glycoprotein-mediated drug resistant tumor cells.
    Kobayashi T; Ishida T; Okada Y; Ise S; Harashima H; Kiwada H
    Int J Pharm; 2007 Feb; 329(1-2):94-102. PubMed ID: 16997518
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of pH-sensitive liposomes that efficiently retain encapsulated doxorubicin (DXR) in blood.
    Ishida T; Okada Y; Kobayashi T; Kiwada H
    Int J Pharm; 2006 Feb; 309(1-2):94-100. PubMed ID: 16364578
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor targeting of doxorubicin by anti-MT1-MMP antibody-modified PEG liposomes.
    Hatakeyama H; Akita H; Ishida E; Hashimoto K; Kobayashi H; Aoki T; Yasuda J; Obata K; Kikuchi H; Ishida T; Kiwada H; Harashima H
    Int J Pharm; 2007 Sep; 342(1-2):194-200. PubMed ID: 17583453
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of Long-Circulating and Fusogenic Liposomes Co-encapsulating Paclitaxel and Doxorubicin in Synergistic Ratio for the Treatment of Breast Cancer.
    Roque MC; Franco MS; Vilela JMC; Andrade MS; de Barros ALB; Leite EA; Oliveira MC
    Curr Drug Deliv; 2019; 16(9):829-838. PubMed ID: 31622204
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Investigation of the antitumor activity and toxicity of long-circulating and fusogenic liposomes co-encapsulating paclitaxel and doxorubicin in a murine breast cancer animal model.
    Franco MS; Roque MC; de Barros ALB; de Oliveira Silva J; Cassali GD; Oliveira MC
    Biomed Pharmacother; 2019 Jan; 109():1728-1739. PubMed ID: 30551427
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Enhanced Efficacy of Intracellular Delivery of Doxorubicin/C6-Ceramide Combination Mediated by the F3 Peptide/Nucleolin System Is Supported by the Downregulation of the PI3K/Akt Pathway.
    Cruz AF; Caleiras MB; Fonseca NA; Gonçalves N; Mendes VM; Sampaio SF; Moura V; Melo JB; Almeida RD; Manadas B; Simões S; Moreira JN
    Cancers (Basel); 2021 Jun; 13(12):. PubMed ID: 34207464
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeted and intracellular triggered delivery of therapeutics to cancer cells and the tumor microenvironment: impact on the treatment of breast cancer.
    Moura V; Lacerda M; Figueiredo P; Corvo ML; Cruz ME; Soares R; de Lima MC; Simões S; Moreira JN
    Breast Cancer Res Treat; 2012 May; 133(1):61-73. PubMed ID: 21805188
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PEGylated liposomal doxorubicin targeted to α5β1-expressing MDA-MB-231 breast cancer cells.
    Shroff K; Kokkoli E
    Langmuir; 2012 Mar; 28(10):4729-36. PubMed ID: 22268611
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeted and heat-triggered doxorubicin delivery to tumors by dual targeted cationic thermosensitive liposomes.
    Dicheva BM; ten Hagen TL; Schipper D; Seynhaeve AL; van Rhoon GC; Eggermont AM; Koning GA
    J Control Release; 2014 Dec; 195():37-48. PubMed ID: 25176578
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hyaluronic acid modified pH-sensitive liposomes for targeted intracellular delivery of doxorubicin.
    Paliwal SR; Paliwal R; Agrawal GP; Vyas SP
    J Liposome Res; 2016 Dec; 26(4):276-87. PubMed ID: 26784587
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improved therapeutic activity of folate-targeted liposomal doxorubicin in folate receptor-expressing tumor models.
    Gabizon A; Tzemach D; Gorin J; Mak L; Amitay Y; Shmeeda H; Zalipsky S
    Cancer Chemother Pharmacol; 2010 May; 66(1):43-52. PubMed ID: 19779718
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human epidermal growth factor receptor-2 antibodies enhance the specificity and anticancer activity of light-sensitive doxorubicin-labeled liposomes.
    Li Q; Tang Q; Zhang P; Wang Z; Zhao T; Zhou J; Li H; Ding Q; Li W; Hu F; Du Y; Yuan H; Chen S; Gao J; Zhan J; You J
    Biomaterials; 2015 Jul; 57():1-11. PubMed ID: 25956192
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined targeting of perivascular and endothelial tumor cells enhances anti-tumor efficacy of liposomal chemotherapy in neuroblastoma.
    Loi M; Marchiò S; Becherini P; Di Paolo D; Soster M; Curnis F; Brignole C; Pagnan G; Perri P; Caffa I; Longhi R; Nico B; Bussolino F; Gambini C; Ribatti D; Cilli M; Arap W; Pasqualini R; Allen TM; Corti A; Ponzoni M; Pastorino F
    J Control Release; 2010 Jul; 145(1):66-73. PubMed ID: 20346382
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro and in vivo targeting of immunoliposomal doxorubicin to human B-cell lymphoma.
    Lopes de Menezes DE; Pilarski LM; Allen TM
    Cancer Res; 1998 Aug; 58(15):3320-30. PubMed ID: 9699662
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drug release rate influences the pharmacokinetics, biodistribution, therapeutic activity, and toxicity of pegylated liposomal doxorubicin formulations in murine breast cancer.
    Charrois GJ; Allen TM
    Biochim Biophys Acta; 2004 May; 1663(1-2):167-77. PubMed ID: 15157619
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.